论文部分内容阅读
目的 :研究多个耐药基因P -糖蛋白 (P -gp)、谷胱甘肽S -转移酶 (GST -π)、DNA拓朴异构酶Ⅱ (Topo -Ⅱ )在卵巢癌组织中表达 ,探讨其在卵巢癌化学治疗耐药中的作用及与临床病理学特征间的关系。方法 :应用免疫组织化学技术 (SP法 )对 37例卵巢癌 ,10例卵巢良性肿瘤和 8例正常卵巢组织中P -gp、GST -π、Topo -Ⅱ表达状况进行测定。 结果 :P -gp、GST -π和Topo -Ⅱ在卵巢癌组织中阳性表达均高于良性肿瘤和正常组织对照组 ;GST -π、Topo -Ⅱ在低分化癌中阳性率明显高于中高分化癌 ,但与肿瘤组织类型无关。GST -π与临床分期有关。P -gp表达与卵巢癌组织类型、分化、分期均无关。 3者在卵巢癌组织中存在共同表达。结论 :卵巢癌存在原发性耐药并涉及多个耐药基因的共同表达。联合检测对前瞻性预测化疗药物敏感性和判断化疗疗效具有指导意义
Objective: To investigate the expression of multiple drug resistance genes P-gp, GST-π and Topo-Ⅱ in ovarian cancer Its role in chemoresistance in ovarian cancer and its relationship with clinicopathological features. Methods: The expression of P-gp, GST-π and Topo-Ⅱ in 37 cases of ovarian cancer, 10 cases of benign ovarian tumor and 8 cases of normal ovarian tissue were determined by immunohistochemistry (SP method). Results: The positive expression rates of P-gp, GST-π and Topo-Ⅱ in ovarian cancer tissues were significantly higher than those in benign tumors and normal tissues. The positive rates of GST-π, Topo-Ⅱ in poorly differentiated carcinoma were significantly higher than those in moderately well- Cancer, but not with the type of tumor tissue. GST-π and clinical stage related. The expression of P-gp was not related to the type, differentiation and staging of ovarian cancer. 3 in ovarian cancer exist in the common expression. Conclusion: Ovarian cancer has primary drug resistance and co-expression of multiple drug resistance genes. Joint detection of the prospective predictive chemotherapy drug sensitivity and determine the efficacy of chemotherapy guidance